Adding to immune function

Admune Therapeutics LLC is developing a heterodimeric complex of IL-15 to boost the immune system's response to cancer immunotherapies by increasing the number of antitumor lymphocytes overall and in the vicinity of tumors.

Tumors' responses to immunotherapy depend in part on the appropriate balance of immune cells that carry out an antitumor response vs. those that promote tolerance. President and CEO Sergio Finkielsztein said higher levels of tumor-infiltrating lymphocytes have been associated with better clinical outcomes, particularly in trials of checkpoint-targeting agents like PD-1 inhibitors...